Proactive Investors - Run By Investors For Investors

Avacta’s CTO to present Affimer data at Biomarkers and Precision Medicine Congress

The biotech company said Dr Matt Johnson would present data showing how the Affimer technology can be used to simplify diagnostics and other immunoassays
Conference speaker
The BPMC gathers over 300 delegates from biotech firms, global pharma companies and academic institutions

Avacta Group Plc’s (LON:AVCT) chief technology officer, Dr Matt Johnson, will present new data for the firm’s Affirmer range of research tools and diagnostics reagents at the Biomarkers and Precision Medicine Congress (BPMC) in San Diego on 12 October.

The biotech company said Johnson would present data showing how the Affimer technology can be used to simplify diagnostics and other immunoassays, as well as showing that immunoassays built using Affimers perform as well as, and better than, equivalent assays built using antibodies.

READ: Avacta rises as it secures licensing deal with New England Biolabs for Affimer technology

Avacta added that Johnson would also speak about a class of Affimers that captures antibodies but only when the antibodies are bound to their own targets, offering a route to improving an important type of diagnostic test to have a more specific and clearer result, the commercial potential of which was “significant”.

The BPMC gathers over 300 delegates from leading biotech companies, global pharma organisations and internationally renowned academic institutions to discuss key issues in biomarker research, companion diagnostics, personalised medicine and clinical biomarkers.

View full AVCT profile View Profile

Avacta Group PLC Timeline

CN Research
April 09 2019

Related Articles

dna strand
May 08 2019
The latest update reveals the company significant clinical and commercial milestones in sight
1557403923_iron.jpg
May 09 2019
Here we take a look under the hood of Shield Therapeutics
scientists in a lab
January 30 2019
The technology first drew the attention of ChemioCare CEO Pedro Lichtinger years ago while he oversaw Pfizer's global primary care business

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use